SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Fabio Blandini, Marie-Therese Armentero, Dopamine receptor agonists for Parkinson's disease, Expert Opinion on Investigational Drugs, 2014, 23, 3, 387

    CrossRef

  2. 2
    Amaal Al Dakheel, Nicolas M Phielipp, Janis Miyasaki, Evidence-based advances in the treatment of motor features of Parkinson’s disease, Neurodegenerative Disease Management, 2013, 3, 4, 331

    CrossRef

  3. 3
    S. Thobois, E. Lhommee, H. Klinger, C. Ardouin, E. Schmitt, A. Bichon, A. Kistner, A. Castrioto, J. Xie, V. Fraix, P. Pelissier, S. Chabardes, P. Mertens, J.-L. Quesada, J.-L. Bosson, P. Pollak, E. Broussolle, P. Krack, Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil, Brain, 2013, 136, 5, 1568

    CrossRef

  4. 4
    Carlos Zúñiga-Ramírez, Federico Micheli, Preladenant: an adenosine A2Areceptor antagonist for Parkinson’s disease, Future Neurology, 2013, 8, 6, 639

    CrossRef

  5. 5
    Santiago Perez-Lloret, María Verónica Rey, Pietro Lucca Ratti, Olivier Rascol, Rotigotine transdermal patch for the treatment of Parkinson’s Disease, Fundamental & Clinical Pharmacology, 2013, 27, 1
  6. 6
    Charity G. Moore, Margaret Schenkman, Wendy M. Kohrt, Anthony Delitto, Deborah A. Hall, Daniel Corcos, Study in Parkinson Disease of Exercise (SPARX): Translating high-intensity exercise from animals to humans, Contemporary Clinical Trials, 2013, 36, 1, 90

    CrossRef

  7. You have free access to this content7
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  8. 8
    Omar M. E. Abdel-Salam, Amany A. Sleem, Nermeen Shafee, The dopamine agonist piribedil exerts hepatoprotective effects on carbon tetrachloride-induced hepatic damage, Comparative Clinical Pathology, 2013, 22, 3, 413

    CrossRef

  9. 9
    Manfred Gerlach, Paul Halley, Peter Riederer, Maarten van den Buuse, The effect of piribedil on l-DOPA-induced dyskinesias in a rat model of Parkinson’s disease: differential role of α2 adrenergic mechanisms, Journal of Neural Transmission, 2013, 120, 1, 31

    CrossRef

  10. 10
    Valerie Suski, Mark Stacy, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  11. 11
    Valerie Suski, Mark Stacy, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  12. 12
    Yoshikuni Mizuno, An update on the management of juvenile and young-onset Parkinson’s disease, Future Neurology, 2012, 7, 5, 581

    CrossRef

  13. 13
    Shin Hisahara, Shun Shimohama, Dopamine Receptors and Parkinson's Disease, International Journal of Medicinal Chemistry, 2011, 2011, 1

    CrossRef

  14. 14
    Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  15. 15
    Santiago Perez-Lloret, Olivier Rascol, Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease, CNS Drugs, 2010, 24, 11, 941

    CrossRef

  16. 16
    Juliana Bronzova, Cristina Sampaio, Robert A. Hauser, Anthony E. Lang, Olivier Rascol, Ad Theeuwes, Serge V. van de Witte, Guus van Scharrenburg, Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease, Movement Disorders, 2010, 25, 6
  17. 17
    Olivier Rascol, Paolo Barone, Robert A. Hauser, Yoshikuni Mizuno, Werner Poewe, Anthony H.V. Schapira, Laurence Salin, Mandy Sohr, Catherine Debieuvre, Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease, Movement Disorders, 2010, 25, 14
  18. 18
    Mark J. Millan, From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease, Pharmacology & Therapeutics, 2010, 128, 2, 229

    CrossRef

  19. 19
    Olivier Rascol, Jean-Philippe Azulay, Olivier Blin, Anne-Marie Bonnet, Christine Brefel-Courbon, Pierre Césaro, Philippe Damier, Bérengère Debilly, Frank Durif, Monique Galitzky, Jean-Marie Grouin, Sylvie Pennaforte, Gabriel Villafane, Sadek Yaici, Yves Agid, Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo-controlled, randomized, double-blind, cross-over study, Movement Disorders, 2010, 25, 3
  20. 20
    Rachel Debs, Valérie Cochen De Cock, Laurence Nègre-Pagès, Marina Aristin, Anna Senard, Olivier Rascol, Thought disorders among non-demented outpatients with Parkinson’s disease: prevalence and associated factors, Journal of Neural Transmission, 2010, 117, 10, 1183

    CrossRef

  21. 21
    Angelo Antonini, Eduardo Tolosa, Yoshikuni Mizuno, Mitsutoshi Yamamoto, Werner H Poewe, A reassessment of risks and benefits of dopamine agonists in Parkinson's disease, The Lancet Neurology, 2009, 8, 10, 929

    CrossRef

  22. 22
    William L. Baker, Dee Silver, C. Michael White, Jeffrey Kluger, Jeffrey Aberle, Aarti A. Patel, Craig I. Coleman, Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis, Parkinsonism & Related Disorders, 2009, 15, 4, 287

    CrossRef

  23. 23
    Ubaldo Bonuccelli, Paolo Del Dotto, Olivier Rascol, Role of dopamine receptor agonists in the treatment of early Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S44

    CrossRef

  24. 24
    Facteurs prédictifs de l’efficacité des agonistes dopaminergiques : résultats de l’enquête Optima-Park, des études Parkinson-Regain et Parkinson-Control, NPG Neurologie - Psychiatrie - Gériatrie, 2008, 8, 46, 8

    CrossRef

  25. 25
    David A Gallagher, Anette Schrag, Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease, CNS Drugs, 2008, 22, 7, 563

    CrossRef

  26. 26
    Ala I Iaconi, Marliese A Zimmerman, Amit S Kulkarni, Rajesh Balkrishnan, Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature, Expert Opinion on Pharmacotherapy, 2008, 9, 2, 163

    CrossRef

  27. 27
    P. Krack, J.-C. Peyrieux, Approche méta-analytique de l’efficacité en monothérapie des agonistes dopaminergiques dans le traitement de la maladie de Parkinson, NPG Neurologie - Psychiatrie - Gériatrie, 2007, 7, 41, 23

    CrossRef

  28. 28
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Early (Uncomplicated) Parkinson's Disease,